Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non–Small-Cell Lung Cancer
- 1 June 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (16) , e147-e150
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These TumorsJournal of Thoracic Oncology, 2011
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK InhibitorsNew England Journal of Medicine, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 2008
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapyNature Clinical Practice Oncology, 2006
- Oncogenic protein tyrosine kinasesCellular and Molecular Life Sciences, 2004
- Molecular Biology of Anaplastic Lymphoma Kinase–Positive Anaplastic Large-Cell LymphomaJournal of Clinical Oncology, 2002
- Expression of ALK1 and p80 in Inflammatory Myofibroblastic Tumor and Its Mesenchymal Mimics: A Study of 135 CasesLaboratory Investigation, 2002